Aztreonam avibactam susceptibility testing is an important part of evaluating whether an Enterobacterales isolate is susceptible to this beta-lactam/beta-lactamase inhibitor combination. As aztreonam-avibactam has become an established option for selected difficult-to-treat Gram-negative infections, clinical laboratories need reliable antimicrobial susceptibility testing (AST) methods and appropriate interpretive criteria.
The interpretation of an aztreonam-avibactam result depends on the organism, testing method, applicable breakpoint system and laboratory standards being used. In particular, FDA/CLSI and EUCAST criteria should not be mixed because their interpretive categories and breakpoint approaches differ.
This article explains aztreonam avibactam MIC testing, susceptibility breakpoints, broth microdilution, disk diffusion, gradient diffusion methods and important considerations for MBL-producing Enterobacterales.
Important: Susceptibility testing should be performed and interpreted by qualified clinical microbiology laboratories using current, locally applicable standards. An MIC result should not be interpreted in isolation from the organism, infection, patient factors and applicable clinical guidance.
What Is Aztreonam Avibactam Susceptibility Testing?
Antimicrobial susceptibility testing determines how susceptible or resistant a bacterial isolate is to an antimicrobial agent.
For aztreonam-avibactam, testing generally aims to determine the minimum inhibitory concentration (MIC) or a corresponding disk-diffusion result.
The MIC is the lowest concentration of an antimicrobial combination that prevents visible bacterial growth under standardized test conditions.
A laboratory can then compare the measured MIC with an applicable breakpoint to categorize the isolate.
Depending on the breakpoint system, the result may be reported as:
- Susceptible (S)
- Susceptible, increased exposure (I) where applicable
- Resistant (R)
The important point is that an MIC number by itself does not automatically mean that an organism is susceptible or resistant. The MIC must be interpreted using the appropriate breakpoint system.
Why Is Aztreonam Avibactam MIC Testing Important?
Aztreonam-avibactam has a distinctive mechanism against certain beta-lactamase-producing Gram-negative bacteria.
Aztreonam is stable against hydrolysis by metallo-beta-lactamases (MBLs), while avibactam inhibits several serine beta-lactamases that may otherwise hydrolyze aztreonam.
This is particularly relevant for MBL-producing Enterobacterales, where an isolate may carry an MBL such as NDM together with other beta-lactamases.
However, detecting an MBL does not eliminate the need for susceptibility testing.
The 2026 IDSA guidance specifically notes that identification of carbapenemase genes does not replace AST and that susceptibility testing should still be pursued for relevant agents.
Therefore, aztreonam avibactam susceptibility testing provides an important laboratory component for assessing the activity of the combination against a particular isolate.
Aztreonam Avibactam MIC Breakpoints
Breakpoint systems have evolved as additional microbiological, pharmacokinetic/pharmacodynamic and clinical data have become available.
For Enterobacterales, current U.S. criteria use the following MIC interpretation:
| Interpretation | Aztreonam/Avibactam MIC |
|---|---|
| Susceptible | ≤4/4 µg/mL |
| Intermediate | 8/4 µg/mL |
| Resistant | ≥16/4 µg/mL |
The notation 4/4 µg/mL represents aztreonam at 4 µg/mL with avibactam maintained at a fixed concentration of 4 µg/mL.
The FDA has recognized aztreonam-avibactam susceptibility interpretive criteria for Enterobacterales, including disk-diffusion breakpoints.
The 2026 IDSA AMR guidance also lists ≤4/4 µg/mL as the CLSI susceptible breakpoint for aztreonam-avibactam against Enterobacterales.
EUCAST Aztreonam Avibactam Breakpoints
EUCAST uses a different interpretation framework.
For Enterobacterales, EUCAST has established:
| Interpretation | MIC |
|---|---|
| Susceptible | ≤4 mg/L |
| Resistant | >4 mg/L |
There is no intermediate category in this EUCAST framework.
EUCAST’s breakpoint-setting process incorporates factors such as MIC distributions, pharmacokinetics, pharmacodynamics, dosage, resistance mechanisms and clinical outcome data.
This is why laboratories should not interchange FDA/CLSI and EUCAST categories when reporting results.
Always use the breakpoint system applicable to the laboratory and reporting environment.
How Is Aztreonam Avibactam Susceptibility Tested?
Several laboratory methods can be used to evaluate aztreonam-avibactam susceptibility.
The major approaches include:
- Broth microdilution
- Disk diffusion
- Gradient diffusion
- Other validated susceptibility systems where applicable
The reference methodology and interpretive criteria should follow current standards and validated laboratory procedures.
Broth Microdilution for Aztreonam Avibactam
Broth microdilution (BMD) is an important reference method for determining MICs.
In this method, standardized bacterial inocula are exposed to different concentrations of the antimicrobial combination in microdilution wells.
For aztreonam-avibactam testing, avibactam is maintained at a defined fixed concentration while aztreonam concentrations are varied.
The resulting MIC can then be interpreted against the applicable breakpoint.
FDA regulatory evaluation of aztreonam-avibactam susceptibility testing included broth microdilution and established quality-control ranges for the combination.
Because MIC determination is sensitive to methodological conditions, laboratories need standardized procedures for inoculum preparation, media, incubation and interpretation.
Aztreonam Avibactam Disk Diffusion Testing
Disk diffusion provides another phenotypic method for evaluating susceptibility.
In disk diffusion, a standardized bacterial suspension is inoculated onto agar and an antimicrobial disk is applied to the surface.
After incubation, the inhibition zone is measured.
For aztreonam-avibactam, the FDA has recognized disk-diffusion breakpoints for Enterobacterales.
FDA evaluation identified a 30/20 µg aztreonam-avibactam disk for the disk-diffusion method, corresponding to aztreonam/avibactam.
The zone diameter is then interpreted according to the applicable validated breakpoint criteria.
Gradient Diffusion and ETEST for Aztreonam Avibactam
Gradient diffusion is another approach being evaluated and implemented for aztreonam-avibactam susceptibility testing.
A 2026 multicenter study evaluated an aztreonam-avibactam gradient diffusion strip against reference broth microdilution across 650 Enterobacterales isolates.
Using FDA criteria, the combined dataset demonstrated approximately 95.7% essential agreement and 98.0% categorical agreement, with very major errors at 0% in the reported analysis. Performance differed when EUCAST criteria were applied, particularly because EUCAST does not define an intermediate category.
These findings support gradient diffusion as a practical testing approach for many Enterobacterales, but laboratories should use the specific validated method and applicable interpretive criteria rather than assuming that all gradient strips or platforms are interchangeable.
Aztreonam Avibactam Susceptibility Testing in MBL-Producing Enterobacterales
MBL-producing Enterobacterales are one of the most important contexts for aztreonam-avibactam testing.
Common MBLs include:
- NDM
- VIM
- IMP
Aztreonam itself is stable against hydrolysis by MBLs, but additional serine beta-lactamases can compromise aztreonam activity.
Avibactam can inhibit several of those serine beta-lactamases, allowing aztreonam to retain activity in some organisms carrying multiple resistance mechanisms.
However, susceptibility is not guaranteed.
Resistance can arise through mechanisms including:
- alterations affecting PBP3
- permeability changes
- porin alterations
- additional beta-lactamase mechanisms
- combinations of resistance mechanisms
Therefore, MBL detection and aztreonam-avibactam susceptibility testing answer different but complementary questions.
One identifies an important resistance mechanism; the other evaluates the observed antimicrobial susceptibility phenotype.
Does an NDM Result Automatically Mean Aztreonam Avibactam Is Susceptible?
No.
The presence of an NDM or another MBL provides valuable information about the resistance mechanism, but it should not be treated as a substitute for AST.
The 2026 IDSA guidance reports that aztreonam-avibactam is generally active against MBL-producing Enterobacterales, while also emphasizing the importance of susceptibility testing.
This distinction is especially important because bacterial resistance is often multifactorial.
An isolate may carry an MBL together with other beta-lactamases, porin changes or target-site alterations.
Consequently:
Resistance mechanism testing + phenotypic susceptibility testing = more complete laboratory information.
Aztreonam Avibactam MIC vs Aztreonam MIC
Aztreonam alone and aztreonam-avibactam should not be treated as equivalent susceptibility tests.
Avibactam can inhibit susceptible serine beta-lactamases that would otherwise hydrolyze aztreonam.
As a result, the MIC of aztreonam alone may be substantially different from the MIC observed when avibactam is present.
This is one reason why laboratories require specific interpretive criteria and validated methodologies for the combination.
A high aztreonam MIC does not automatically predict the same result for aztreonam-avibactam.
Why the Avibactam Concentration Matters in MIC Testing
Avibactam is not simply added as an unrestricted second antimicrobial.
For standardized aztreonam-avibactam MIC testing, avibactam is maintained at a defined concentration.
Current FDA-recognized MIC criteria use a fixed avibactam concentration of 4 µg/mL alongside the tested aztreonam concentrations.
This allows susceptibility results to be interpreted using a standardized combination rather than an uncontrolled range of inhibitor concentrations.
What About Pseudomonas aeruginosa?
Aztreonam-avibactam susceptibility testing should not be generalized from Enterobacterales to every Gram-negative organism.
The 2026 IDSA guidance states that aztreonam-avibactam has limited activity against MBL-producing Pseudomonas aeruginosa, and that neither CLSI nor FDA susceptibility breakpoints are available for this organism.
This is an important example of why the organism must be considered before applying an MIC breakpoint.
A breakpoint established for Enterobacterales should not automatically be transferred to Pseudomonas or another organism.
Aztreonam Avibactam Susceptibility Testing: Key Laboratory Considerations
When interpreting an aztreonam-avibactam AST result, laboratories should consider:
1. Organism identification
Breakpoints are organism-specific.
2. Testing methodology
Broth microdilution, disk diffusion and gradient diffusion have different procedures and validation requirements.
3. Breakpoint system
FDA/CLSI and EUCAST criteria can differ.
4. MIC value
The numerical MIC should be interpreted against the appropriate breakpoint.
5. Resistance mechanism
NDM, VIM, IMP and other resistance determinants provide useful microbiological context.
6. Quality control
Validated QC procedures are essential for reliable AST.
7. Clinical context
A laboratory susceptibility result does not by itself determine the appropriate treatment for an individual patient.
2026 Updates in Aztreonam Avibactam Susceptibility Testing
The susceptibility-testing landscape has continued to develop.
In February 2026, the FDA listed recognition of disk-diffusion breakpoints for aztreonam-avibactam against Enterobacterales.
At the same time, newer studies have evaluated gradient diffusion methods against reference broth microdilution, providing additional evidence for practical laboratory implementation.
EUCAST also continues to update its clinical breakpoint framework and guidance for situations where breakpoints are unavailable. Its 2026 guidance emphasizes that laboratories should not simply borrow breakpoints from another breakpoint-setting organization without appropriate review.
This makes keeping AST procedures and interpretive criteria current particularly important for newer antimicrobial combinations.
Aztreonam Avibactam Susceptibility and Meblanios
Meblanios is an Aztreonam and Avibactam injection from AIONIOS Pharma, containing the aztreonam-avibactam combination.
For product-related information, readers can refer to the dedicated Meblanios product page on the AIONIOS Pharma website.
However, susceptibility breakpoints are determined by microbiological and regulatory standards and should not be inferred solely from a product name.
For scientific information about aztreonam-avibactam, see the broader Aztreonam and Avibactam resource on AIONIOS Pharma.
Internal links to add:
- Aztreonam and Avibactam →
/aztreonam-and-avibactam/ - Aztreonam Avibactam Injection →
/aztreonam-avibactam-injection/ - Aztreonam Avibactam MBL Resistance →
/mbl-resistance-aztreonam-avibactam/ - Aztreonam Avibactam Dosage →
/aztreonam-avibactam-dosage-administration/ - Aztreonam Avibactam Renal Dosing →
/aztreonam-avibactam-renal-dosing/ - Aztreonam Avibactam Clinical Trials →
/aztreonam-avibactam-clinical-trials/ - Meblanios Product Page →
/product/meblanios/
Important: Existing duplicate Meblanios articles should not all be linked with equal prominence. The product/entity signals should be concentrated on the canonical Meblanios product page.
Frequently Asked Questions
What is aztreonam avibactam susceptibility testing?
Aztreonam avibactam susceptibility testing is laboratory testing used to determine the activity of the aztreonam-avibactam combination against a bacterial isolate, commonly through MIC or disk-diffusion methods.
What is the susceptible MIC breakpoint for aztreonam-avibactam?
For Enterobacterales, the current FDA/CLSI susceptible MIC breakpoint is ≤4/4 µg/mL, while EUCAST uses ≤4 mg/L as its susceptible breakpoint.
What is the aztreonam avibactam resistant breakpoint?
Under FDA/CLSI criteria for Enterobacterales, ≥16/4 µg/mL is resistant. Under EUCAST, the resistant category is >4 mg/L.
Can aztreonam-avibactam be tested by disk diffusion?
Yes. FDA-recognized disk-diffusion breakpoints are available for Enterobacterales, and a 30/20 µg aztreonam-avibactam disk has been evaluated for this purpose.
Is broth microdilution used for aztreonam-avibactam?
Yes. Broth microdilution is an important reference method for determining aztreonam-avibactam MICs and has been used in regulatory and performance evaluations.
Does an NDM-producing isolate automatically mean it is susceptible to aztreonam-avibactam?
No. NDM detection identifies an MBL resistance mechanism, but susceptibility testing is still required to evaluate the isolate’s phenotype.
Are aztreonam-avibactam breakpoints the same for all Gram-negative bacteria?
No. Breakpoints are organism-specific. For example, the 2026 IDSA guidance notes that CLSI and FDA susceptibility breakpoints are not available for aztreonam-avibactam against MBL-producing Pseudomonas aeruginosa.
Conclusion
Aztreonam avibactam susceptibility testing has become increasingly important as laboratories encounter Enterobacterales carrying complex beta-lactamase resistance mechanisms.
MIC testing, broth microdilution, disk diffusion and gradient diffusion can provide valuable susceptibility information when performed using validated procedures and current interpretive criteria.
For Enterobacterales, current FDA/CLSI criteria use ≤4/4 µg/mL as susceptible, 8/4 µg/mL as intermediate and ≥16/4 µg/mL as resistant, while EUCAST uses a different breakpoint framework.
The key principle is simple: the organism, testing method, breakpoint system and resistance mechanism all matter when interpreting an aztreonam-avibactam susceptibility result.